SB
Suresh Babu Jalagam
About Suresh Babu Jalagam
Suresh Babu Jalagam has 17 years in corporate governance. Holds Additional Director and Director roles. Currently with 2 companies, including Anica Labs Private Limited and Ainesh Pharma Private Limited. Formerly with 2 companies, such as Rishon Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Ainesh Pharma Private Limited
U24304AP2017PTC105103
|
Director | 08 Feb 2017 | 2017 | Active |
Ingentis Pharma Private Limited
U24304AP2020PTC115633
|
Director | 05 Sep 2020 | 2020 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Rishon Laboratories Private Limited
U24110TG2009PTC063486
|
Managing Director | 29 Apr 2009 | 2009 | Active |
Anica Labs Private Limited
U24230TG2005PTC045913
|
Additional Director | 11 Sep 2012 | 2005 | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Suresh Babu Jalagam
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Suresh Babu Jalagam
Suresh Babu Jalagam has 17 years in corporate governance. Holds Additional Director and Director roles. Currently with 2 companies, including Anica Labs Private Limited and Ainesh Pharma Private Limited. Formerly with 2 companies, such as Rishon Laboratories Private Limited. Engaged in General Business. Contributes to corporate operations.
Suresh Babu Jalagam is associated with 2 companies as Additional Director and Director.
Suresh Babu Jalagam has expertise in General Business.
Suresh Babu Jalagam has 17 years in corporate governance.